Its Stock Has Paid Off Big Time For Altamira Therapeutics Ltd.

Altamira Therapeutics Ltd. (NASDAQ: CYTO) stock jumped 2.09% on Wednesday to $0.88 against a previous-day closing price of $0.86. With 12.73 million shares changed hands, the volume of the stock remained heavier than its average volume of 2.82 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $1.1800 whereas the lowest price it dropped to was $0.8167. The 52-week range on CYTO shows that it touched its highest point at $18.40 and its lowest point at $0.73 during that stretch. Beta for the stock currently stands at 1.28.

Unlock the Hottest Top 10 Penny Stocks Today! Discover Now

Dive into the world of lucrative penny stocks with MarketClub's groundbreaking "Smart Scan" technology! Get an instant snapshot of the top 50 high volume stocks with a clear direction and outstanding liquidity - in other words, the strongest trending. To unlock this exclusive list, simply provide your first name, last name, and email for instant access.

Gain Access to Top 10 Penny Stocks Now!.


Price Performance and Earnings:

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of CYTO was up-trending over the past week, with a rise of 0.92%, but this was down by -11.31% over a month. Three-month performance dropped to -64.74% while six-month performance fell -83.74%. The stock lost -94.89% in the past year, while it has lost -81.90% so far this year.

Float and Shares Shorts:

At present, 6.99 million CYTO shares are outstanding with a float of 6.91 million shares on hand for trading. On Apr 27, 2023, short shares totaled 95560.0, which was 1.37% higher than short shares on Mar 30, 2023. In addition to Dr. Thomas Meyer Ph.D. as the firm’s Founder, Chairman, CEO & MD, Mr. Marcel Gremaud CPA serves as its Chief Financial Officer.

Institutional Ownership:

Through their ownership of 0.61% of CYTO’s outstanding shares, institutional investors have minority control over the company. Other institutions hold 0.41% of CYTO, in contrast to 0.08% held by mutual funds. Shares owned by individuals account for –. As the largest shareholder in CYTO with 0.26% of the stake, Citigroup Global Markets, Inc. holds 3,074 shares worth 3,074. A second-largest stockholder of CYTO, UBS Securities LLC, holds 1,532 shares, controlling over 0.13% of the firm’s shares. Morgan Stanley & Co. LLC is the third largest shareholder in CYTO, holding 525 shares or 0.05% stake. With a 0.08% stake in CYTO, the Fidelity Nasdaq Composite Index F is the largest stakeholder. A total of 943 shares are owned by the mutual fund manager.

An Overview of Recent Financials:

Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. Over the past year, revenue came in at $1.29M while operating income stood at -$18.13M. EBITDA for the full year was -$18.01M.

Analysts Ratings:

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for CYTO since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential. With CYTO analysts setting a high price target of $286.10 and a low target of $286.10, the average target price over the next 12 months is $286.10. Based on these targets, CYTO could surge 32411.36% to reach the target high and rise by 32411.36% to reach the target low. Reaching the average price target will result in a growth of 32411.36% from current levels.

EPS: Estimates vs Actual

It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy.

Leave a Comment

Your email address will not be published. Required fields are marked *